Febris Therapeutics Highlights Burdens in FDA Investigational New Drug Application Requirements
2026-05-08
PubComNonGov2026-05-08
Carter Struck
WASHINGTON, May 8 -- Febris Therapeutics Inc., a pre-clinical biotechnology company focused on developing first-in-class antibiotics targeting Gram-negative ESKAPE pathogens and biothreat organisms, s . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and individuals; as well as 'gathered' public policy information, including news releases, reports, speeches. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
WASHINGTON, May 8 -- Febris Therapeutics Inc., a pre-clinical biotechnology company focused on developing first-in-class antibiotics targeting Gram-negative ESKAPE pathogens and biothreat organisms, s . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and individuals; as well as 'gathered' public policy information, including news releases, reports, speeches. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
Copyright © Targeted News Service, 2026